Xenon Pharmaceuticals Inc  

(Public, NASDAQ:XENE)   Watch this stock  
Find more results for TEVA BIOPHARMACEUTICALS, INC
15.60
-0.41 (-2.56%)
After Hours: 15.60 0.00 (0.00%)
Dec 19, 4:28PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 15.58 - 17.15
52 week 9.21 - 18.48
Open 16.00
Vol / Avg. 26,654.00/72,513.00
Mkt cap 222.40M
P/E 55.10
Div/yield     -
EPS 0.28
Shares 14.18M
Beta     -
Inst. own 0%
Dec 15, 2014
Q3 2014 Xenon Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 25.27% 43.98%
Operating margin 23.40% 35.50%
EBITD margin - 38.08%
Return on average assets 9.87% 20.43%
Return on average equity - -
Employees 63 -
CDP Score - -

Address

200-3650 Gilmore Way
BURNABY, BC V5G 4W8
Canada
+1-604-4843300 (Phone)
+1-604-4843450 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Xenon Pharmaceuticals Inc. (Xenon) is a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications. It has an integrated platform, which includes in-house capabilities for human genetics, small molecule drug discovery, and preclinical and clinical development. Its pharmaceutical partners include Teva Pharmaceutical Industries, Ltd. (Teva) (through its subsidiary, Ivax International GmbH), Genentech, Inc. (Genentech), and Merck & Co., Inc. (Merck) (through its affiliate, Essex Chemie AG).

Officers and directors

Michael M. Tarnow Chairman of the Board
Age: 70
Bio & Compensation  - Reuters
Ian C. Mortimer MBA., CPA., CMA. Chief Financial Officer
Age: 38
Bio & Compensation  - Reuters
Gary J. Bridger Ph.D. Executive Vice President of Research and Development
Age: 51
Bio & Compensation  - Reuters
Robin Paul Sherrington Ph.D. Senior Vice President of Business and Corporate Development
Age: 53
Bio & Compensation  - Reuters
Charles M. Cohen Ph.D. Vice President - Biology
Age: 66
Bio & Compensation  - Reuters
Yigal Paul Goldberg M.B., ChB., Ph.D. Vice President of Clinical Development
Age: 54
Bio & Compensation  - Reuters
Karen G Corraini J.D. General Counsel and Corporate Secretary
Age: 59
Bio & Compensation  - Reuters
Simon Neil Pimstone M.B., ChB., Ph.D. President, Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
Mohammad Azab MBA,, M.B., ChB. Director
Age: 58
Bio & Compensation  - Reuters
Johnston Livingston Evans Director
Age: 66
Bio & Compensation  - Reuters